David A. Kennard
Corporate Officer/Principal at Royal Pharmaceutical Society of Great Britain
David A. Kennard active positions
| Companies | Position | Start | End |
|---|---|---|---|
Royal Pharmaceutical Society of Great Britain
 Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | - | - |
Career history of David A. Kennard
Former positions of David A. Kennard
| Companies | Position | Start | End |
|---|---|---|---|
| SILENCE THERAPEUTICS PLC | Chief Operating Officer | - | - |
NeuroTargets Ltd.
 NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Director/Board Member | 2004-07-31 | - |
| President | 2004-07-31 | - | |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 2003-12-31 | - |
Training of David A. Kennard
| University of London | Doctorate Degree |
Statistics
International
| United Kingdom | 5 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectoral
| Commercial Services | 3 |
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Private companies | 3 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Royal Pharmaceutical Society of Great Britain
Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
NeuroTargets Ltd.
NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Health Technology |
- Stock Market
- Insiders
- David A. Kennard
- Experience
